

Acenocoumarol

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to warfarin for Other specified diseases of arteries or arterioles Therapeutic equivalent to warfarin for Venous thromboembolism Therapeutic equivalent to warfarin for Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin for Atrial fibrillation

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Cyanocobalamin

Section	Indications
Antianaemia medicines .	Anaemias or other erythrocyte disorders

Dabigatran

Section	Indications
Medicines affecting coagulation Oral > Solid: 110 mg; 150 mg	Venous thromboembolism Other specified atrial fibrillation

Dalteparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for

Acute ischaemic heart disease

Therapeutic equivalent to [enoxaparin](#) for

Venous thromboembolism

Darbepoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Deferasirox

Section

Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Therapeutic equivalent to [deferoxamine](#) for

Thalassaemias

Deferiprone

Section

Other medicines for haemoglobinopathies

Indications

Therapeutic equivalent to [deferasirox](#) for

Other specified sickle cell disorders or other haemoglobinopathies

Therapeutic equivalent to [deferasirox](#) for

Thalassaemias

Deferoxamine

Section

Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Desmopressin

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

Local > Nasal > Spray: 150 µg per actuation (acetate)

Indications

Haemophilia A

Von Willebrand disease

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Emicizumab

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

Haemophilia A

Enoxaparin

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

Acute ischaemic heart disease

Venous thromboembolism

Epoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for

Anaemia due to chronic disease

Epoetin beta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Epoetin theta

Section	Indications
Antianaemia medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

Erythropoiesis-stimulating agents

Section	Indications
Antianaemia medicines Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe	Anaemia due to chronic disease

Ferrous salt

Section	Indications
Antianaemia medicines Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron Oral > Solid > tablet: 60 to 65 mg elemental iron	Iron deficiency anaemia

Ferrous salt + folic acid

Section	Indications
Antianaemia medicines Oral > Solid: 60 mg iron + 2.8 mg Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg	Iron deficiency anaemia Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida

Folic acid

Section

Antianaemia medicines

Oral > Solid: 400 µg

Oral > Liquid: 1 mg per mL

Oral > Solid: 1 mg tablet; 5 mg tablet

Indications

Anencephaly or similar anomalies

Spina bifida

Cephalocele

Folate deficiency anaemia

Heparin sodium

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial

Indications

Acute ischaemic heart disease

Unstable angina

Venous thromboembolism

Hydroxocobalamin

Section

Antianaemia medicines

Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

Indications

Megaloblastic anaemia due to vitamin B12 deficiency

Hydroxycarbamide (hydroxyurea)

Section

Other medicines for haemoglobinopathies

Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Methoxy polyethylene glycol-epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for

Acute ischaemic heart disease

Therapeutic equivalent to [enoxaparin](#) for

Venous thromboembolism

Phytomenadione

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution

Oral > Solid > tablet: 5 mg tablet

Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Haemorrhagic or haematological disorders of fetus or newborn

Protamine sulfate

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

Tranexamic acid

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Haemorrhage, not elsewhere classified

Warfarin

Section

Medicines affecting coagulation

Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)

Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)

Indications

Other specified diseases of arteries or arterioles

Venous thromboembolism

Cerebral ischaemic stroke due to embolic occlusion

Atrial fibrillation